期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非霍奇金淋巴瘤单克隆抗体治疗的研究进展 被引量：2

Research Progress on Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma
下载PDF
导出
摘要 单克隆抗体应用于临床治疗恶性淋巴瘤目前已经取得了明显成效,与传统治疗相比,具有靶向性、不良反应小、能达到体内肿瘤细胞的微量残留等特点。新的抗CD20单克隆抗体为非霍奇金淋巴瘤治疗带来了新的发展,对以美罗华为代表单克隆抗体治疗恶性淋巴瘤的耐药问题带来了新的突破,提出了新策略。 Monoclonal antibody treatment has made great achievement in patients with malignant lymphomas.Comparing with traditional treatment,its advantages are targeted property and little side effect.It also could achieve mininal residal of tumor cell in vivo.The new anti-CD20 monoclonal antibody provides new development for treatment of non-Hodgkin＇s lymphoma and introduces a new strategy to the drug resistance.
作者 温宁笑 袁红梅
机构地区 武警江西省总队医院
出处 《现代诊断与治疗》 CAS 2010年第4期221-223,共3页 Modern Diagnosis and Treatment
关键词 单克隆抗体 淋巴瘤 抗CD20 非霍奇金淋巴瘤 Monclonal antibodies Lymphoma Anti-CD20 Non-Hodgkin＇s lymphoma
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1Maloney DG,Liles TM,Czerwinski DK,et al.Phase Ⅰ clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody(IDEC-C2B8) in patients with recurrent B-cell lymphoma[J].Blood,1994,84(8):2457-2466.
  • 2Marcus R,Hagenbeek A.The therapeutic use of Rituximab in non-Hodgkin's lymphoma[J].Eur J Haematol Suppl,2007,(67):5-14.
  • 3Hagenbeek A.Maintenance or eradication of residual disease in indolent lymphoma:where do we stand?(Editorial)[J].J Clin Oncol,2009,27(10):1540-1542.
  • 4Hochster H,Weller E,Gascoyne RD,et al.Maintenance rituximab after cyclophosphamide,vincristine,and prednisone prolongs progression-free survival in advanced indolent lymphoma:results of the randomized phase Ⅲ ECOG1496 study[J].J Clin Oncol,2009,27(10):1607-1614.
  • 5Cartron G,Dacheux L,Salles G,et al.Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaR Ⅲ a gene[J].Blood,2002,99(3):754-758.
  • 6Gong Q,Ou Q,Ye S,et al.Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy[J].J Immunol,2005,174(2):817-826.
  • 7Vugmeyster Y,Beyer J,Howell K,et al.Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis[J].J Immunother,2005,28(3):212-219.
  • 8Teeling JL,French RR,Cragg MS,et al.Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas[J].Blood,2004,104:1793-1800.
  • 9Hagenbeek A,Plesner T,Johnson P,et al.HuMax-CD20,a novel fully human anti-CD20 monoclonal antibody:results of a phase Ⅰ/Ⅱ trial in relapsed or refractory follicular non-Hodgkins's lymphoma[J].ASH Annual Meeting Abstracts,2005,106:4760.
  • 10Coiffer B,Lepretre S,Pedersen LM,et al.Safety and effcacy of atumumab,a fully human monoclonal anti-CD20 antibody,in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:a phase 1-2 study[J].Blood,2008,111(3):1094-1100.

同被引文献13

  • 1师明磊,胡显文,陈惠鹏,高丽华,李世崇.抗CD20嵌合抗体的表达与活性检测[J].中国生物工程杂志,2005,25(7):34-39. 被引量：4
  • 2陈森,饶青,王建祥,王敏.抗人CD19单链抗体基因的构建、表达及功能测定[J].生物工程学报,2005,21(5):686-691. 被引量：12
  • 3Jemal A,Siegel R, Ward E, et al. Cancer statistics[ J]. CA Cancer J Clin, 2008, 58(2) ; 71-96.
  • 4Riley J K,Sliwkowski M X. CD20: a gene in search of a function[ J]. Semin Oncol, 2000,27(6 Suppl 12) : 17-24.
  • 5Du J, Wang H,Zhong C,et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab[ J].J Biol Chem,2007,282(20) : 15 073-15 080.
  • 6John R G, Steven S H, Jeffrey T R, et al. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependentcellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab [ J ]. Molecular Immu-nology, 2012,50(3) : 134-141.
  • 7Hu S Z, Lousise S, Andrew R, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (sin-gle-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts[ J]. Cancer Res, 1996,56( 13) : 3 055-3 061.
  • 8Verma R, Boleti E, George A J. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expressionsystems[ J]. J Immunol Methods, 1998,216(1/2) : 165-181.
  • 9Castillo J,Milani C,Mendez-Allwood D,et al.Ofatumumab,a second-generation anti-CD20 monoclonal antibody,for the treatment of lymphoproliferative and autoimmune disorders[J].Expert Opin Investig Drugs,2009,18(4):491-500.
  • 10Luo P,Hayes RJ,Chan C,et al.Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening[J].Protein Sci,2002,11(5):1218-1226.

引证文献2

现代诊断与治疗
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部